CompanyWVENasdaqCambridge, MA

Wave Life Sciences, Inc.

Wave Life Sciences develops RNA-targeting medicines using RNAi and RNA editing modalities.

SEC EDGAR ClinicalTrials.gov ir.wavelifesciences.com

424B4Sep 28Latest SEC filing

Sep 9Latest story

September 2026

Wave posts results for terminated WVE-004 OLE study in C9orf72 ALS/FTD

Sep 9Trial updateWave Life Sciences, Inc.WVE-004

July 2026

Wave Life Sciences reports Q2 2026 results, advances obesity and AATD pipelines

Jul 30Clinical readoutWave Life Sciences, Inc.